Gonzalo Rebelo De Andrade

Goncalo Rebelo de Andrade is an Investment Committee Member and a partner of the Indaco BIO Fund.

In 2000, Goncalo started working in the development of molecular biology tools for the detection of slow growing human pathogens (Mycobacterium tuberculosis) and later on the detection of food bourne pathogens for the dairy industry. In 2003, Goncalo joined the Genecenter in Munich, Germany to conduct graduate research in asymmetric cell division and protein purification.

At the end of 2008, Goncalo moved to San Francisco to be part of the Gamma-Secretase small molecule inhibitor program at Elan Pharmaceuticals. Late in 2009, he joined Bioalvo, a Portuguese start-up, as a scientist to lead new lead identification and development activities in inflammatory diseases and neurodegeneration, up to 2013. Having developed a taste for IP in the pharmaceutical field, Goncalo started working, in 2009, as an independent IP expert at RPA, Furtado and collaborating with Clarke Modet.

In 2013, Goncalo joined the world leader in the development of poorly soluble drugs using amorphous solid dispersions, Hovione, to lead the inhalation business development activities. While there, he also became the General Manager of Hovione Capital in 2015, a corporate venture capital fund dedicated to seed and early investment in medtech and medical device projects across Europe that he set up, run and managed, with Peter Villax and Miguel Calado. Goncalo served as on the board of the invested companies.

In 2019, Goncalo left Hovione Capital to join a Helsinki University spin-off, Nanoform, developing a novel approach to the development of poorly soluble drugs, as the Chief of Business Operations. As part of his tenure, the company has grown from 20 people to 150, expanded the R&D space from 100m2 to 4400m2, received GMP manufacturing certification and has gone public on the Nasdaq First North stock exchange, both in Sweden and in Finland.

Since September 2022, Goncalo is a member of the investment committee at Indaco Bio Fund and a partner of the fund.

Goncalo has an undergraduate degree in Microbiology and Genetics from the University of Lisbon, Portugal and a PhD in Biochemistry / Pharmacy with honors from the Ludwig-Maximillian University, in Munich, Germany.

Goncalo has an MBA from Catolica-Nova/MIT and additional post graduate training from Wharton Business School (licensing and valuation in pharma/biotech), MIT (operations management) and London Business School (Private Equity and Venture Capital).